Equities Analysts Set Expectations for RARE Q1 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a research note issued to investors on Wednesday, November 6th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical company will earn ($1.20) per share for the quarter. HC Wainwright has a “Buy” rating and a $95.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.29) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2025 earnings at ($0.96) EPS.

Several other research analysts have also weighed in on RARE. Barclays dropped their price target on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. The Goldman Sachs Group boosted their price target on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $116.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday. Wells Fargo & Company increased their price target on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, TD Cowen increased their price target on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $86.69.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE opened at $50.52 on Thursday. Ultragenyx Pharmaceutical has a 12-month low of $34.06 and a 12-month high of $60.37. The firm has a market capitalization of $4.66 billion, a P/E ratio of -6.92 and a beta of 0.58. The business has a 50 day simple moving average of $55.32 and a 200 day simple moving average of $48.11.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The business’s revenue for the quarter was up 42.3% compared to the same quarter last year. During the same quarter last year, the company earned ($2.23) earnings per share.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC increased its position in Ultragenyx Pharmaceutical by 103.8% during the 2nd quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company’s stock worth $76,065,000 after purchasing an additional 942,529 shares in the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 137.1% during the first quarter. Avoro Capital Advisors LLC now owns 830,000 shares of the biopharmaceutical company’s stock valued at $38,753,000 after acquiring an additional 480,000 shares during the period. Frazier Life Sciences Management L.P. acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at $17,468,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Ultragenyx Pharmaceutical by 513.8% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 507,095 shares of the biopharmaceutical company’s stock valued at $23,677,000 after purchasing an additional 424,476 shares in the last quarter. Finally, Artal Group S.A. bought a new stake in shares of Ultragenyx Pharmaceutical during the first quarter valued at about $8,308,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Howard Horn sold 7,465 shares of the firm’s stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now owns 92,301 shares of the company’s stock, valued at approximately $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the transaction, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at $124,209,562.25. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,556 shares of company stock worth $1,515,967 in the last 90 days. 5.80% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.